A compound of Formula or a stereoisomeric form thereof, wherein R 1 is phenyl or 2-pyridinyl, each of which is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyl, monohalo-C 1-4 alkyl, polyhalo-C 1-4 alkyl, -C 1-4 alkyl-OH, -CN, -C 1-4 alkyl-O-C 1-4 alkyl, C 3-7 cycloalkyl, -O-C 1-4 alkyl, monohalo-C 1-4 alkyloxy, polyhalo-C 1-4 alkyloxy, SF 5, C 1-4 alkylthio, monohalo-C 1-4 alkylthio, polyhalo-C 1-4 alkylthio; R 2 is selected from the group consisting of hydrogen, C 1 - 4 alkyl, -C 1-4 alkyl-OH, C 3-7 cycloalkyl, monohalo-C 1 - 4 alkyl, polyhalo-C 1 - 4 alkyl, -C 1-4 alkyl-O-C 1-4 alkyl, NR 5a R 5b, Aryl, and Het; wherein Aryl is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1 - 4 alkyl, -C 1-4 alkyl-OH, monohalo-C 1-4 alkyl, polyhalo-C 1-4 alkyl, -CN, -O-C 1-4 alkyl, -OH, -C 1-4 alkyl-O-C 1-4 alkyl, -NR 6a R 6b, -NHC C 1-4 alkyl, -C NR 6a R 6b, -C NH[C C 1-4 alkyl], -S 2 NR 6a R 6b, -S 2 NH[C C 1-4 alkyl], and -SO 2 -C 1-4 alkyl; Het is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, each of which is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1 - 4 alkyl, -C 1-4 alkyl-OH, monohalo-C 1-4 alkyl, polyhalo-C 1-4 alkyl, -CN, -O-C 1-4 alkyl, -OH, -C 1-4 alkyl-O-C 1-4 alkyl, -NR 6a R 6b, -NHC C 1-4 alkyl, -C NR 6a R 6b, -C NH[C C 1-4 alkyl], -S 2NR 6a R 6b, -S 2 NH[C C 1-4 alkyl], and -SO 2 -C 1-4 alkyl; R 5a, R 5b, R 6a and R 6b are each independently hydrogen or C 1-4 alkyl; R 3 is hydrogen or C 1-4 alkyl; and R 4 is selected from the group consisting of hydrogen, C 1-4 alkyl, monohalo-C 1-4 alkyl, polyhalo-C 1-4 alkyl, -C 1-4 alkyl-O-C 1-4 alkyl, and -C 1-4 alkyl-OH; or a N-oxide, or a pharmaceutically acceptable salt or a solvate thereof. R 1 is phenyl or 2-pyridinyl, each of which is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1-4 alkyl, monohalo-C 1-4 alkyl, polyhalo-C 1-4 alkyl, -C 1-4 alkyl-OH, -CN, -C 1-4 alkyl-O-C 1-4 alkyl, C 3-7 cycloalkyl, -O-C 1-4 alkyl, monohalo-C 1-4 alkyloxy, polyhalo-C 1-4 alkyloxy, SF 5, C 1-4 alkylthio, monohalo-C 1-4 alkylthio, polyhalo-C 1-4 alkylthio; R 2 is selected from the group consisting of hydrogen, C 1 - 4 alkyl, -C 1-4 alkyl-OH, C 3-7 cycloalkyl, monohalo-C 1 - 4 alkyl, polyhalo-C 1 - 4 alkyl, -C 1-4 alkyl-O-C 1-4 alkyl, NR 5a R 5b, Aryl, and Het; wherein Aryl is phenyl optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1 - 4 alkyl, -C 1-4 alkyl-OH, monohalo-C 1-4 alkyl, polyhalo-C 1-4 alkyl, -CN, -O-C 1-4 alkyl, -OH, -C 1-4 alkyl-O-C 1-4 alkyl, -NR 6a R 6b, -NHC C 1-4 alkyl, -C NR 6a R 6b, -C NH[C C 1-4 alkyl], -S 2 NR 6a R 6b, -S 2 NH[C C 1-4 alkyl], and -SO 2 -C 1-4 alkyl; Het is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, each of which is optionally substituted with one or more substituents each independently selected from the group consisting of halo, C 1 - 4 alkyl, -C 1-4 alkyl-OH, monohalo-C 1-4 alkyl, polyhalo-C 1-4 alkyl, -CN, -O-C 1-4 alkyl, -OH, -C 1-4 alkyl-O-C 1-4 alkyl, -NR 6a R 6b, -NHC C 1-4 alkyl, -C NR 6a R 6b, -C NH[C C 1-4 alkyl], -S 2NR 6a R 6b, -S 2 NH[C C 1-4 alkyl], and -SO 2 -C 1-4 alkyl; R 5a, R 5b, R 6a and R 6b are each independently hydrogen or C 1-4 alkyl; R 3 is hydrogen or C 1-4 alkyl; and R 4 is selected from the group consisting of hydrogen, C 1-4 alkyl, monohalo-C 1-4 alkyl, polyhalo-C 1-4 alkyl, -C 1-4 alkyl-O-C 1-4 alkyl, and -C 1-4 alkyl-OH; or a N-oxide, or a pharmaceutically acceptable salt or a solvate thereof.